Skip to main content

Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review

Abstract

Compounds derived from biologic sources, or biologicals, are increasingly utilized as therapeutic agents in malignancy. Development of anti-cancer targeted therapies from biologics is increasingly being utilized. Cetuximab, a chimeric monoclonal antibody, is one such anti-cancer targeted therapeutic that has shown efficacy in quelling the rate of patient decline in colorectal, head/neck, and non-small cell lung cancer. However, due to the relatively recent addition of biologic compounds to the therapeutic arsenal, information related to adverse reactions is less well known than those seen in traditional chemotherapeutics. Dermatologic reactions have been demonstrated as the most frequent side effect cited during cetuximab therapy for malignancy; however, other effects may lead to greater morbidity. In general, pulmonary complications of therapeutics can lead to significant morbidity and mortality. The purpose of this review is to compile the various pulmonary side effects seen in patients treated with cetuximab for various malignancies, and to compare the incidence of these adverse reactions to standard therapies.

Background

Biological Therapies

Biologic therapies, or biologicals, are those produced or extracted from a biological source. Based upon the specific agent, biologicals have a myriad of activities and have been used to modulate immunity, increase blood cell production, inhibit tumor growth, and other effects [1]. Over the last 5 years, more than 20% of the compounds approved by United States regulatory authorities were biologics [2]. Despite this explosion in the availability of biologicals, surprisingly limited data exists regarding adverse events associated with their use.

Because these compounds are derived from biologic sources, they have the potential for significant immune activation. Although extensively reported in clinical trials, adverse events are rarely compiled in the medical literature. Giezen and coauthors examined adverse event reporting post-approval for biologicals and suggested that there was a need for increasing awareness to certain risks associated with the therapeutic use of biologicals [2].

Cetuximab (Erbitux®)

One such biologic therapy used in the treatment of malignancy is cetuximab (Erbitux®, ImClone, Branchburg, NJ). Cetuximab is a chimeric monoclonal antibody with inhibitor effects on the epidermal growth factor receptor (EGFR). Cetuximab has been extensively studied and approved [3] for the treatment of metastatic colorectal cancer (MCRC) and squamous cell head/neck cancers (SCCHN), and growing data supports its use in the treatment of other malignancies including non-small cell lung cancer (NSCLC). Cetuximab has been evaluated in the setting of combination therapy or as a single agent in conventional therapy failures. Moreover, cetuximab has been studied for the treatment of various other malignancies including breast cancer and ovarian cancer, hepatocellular cancer, pancreatic cancer, and others.

Through binding to the extracellular domain of EGFR, cetuximab interrupts the signaling cascade resulting in inhibition of cell growth, induction of apoptosis, and decreased matrix metalloproteinase and vascular endothelial growth factor production [3]. EGFR, a member of the ErbB-1 family of receptors, is closely related structurally to other tyrosine kinase receptors including HER2/c-neu (ErbB-2), Her 3 (ErbB-3), and Her 4 (ErbB-4)[4]. Over expression or increased activity of EGFR as seen in some mutations can result malignancy [4].

Cetuximab efficacy has been studied as a single agent as well as in combination with other chemotherapeutic modalities. A randomized controlled clinical trial with 329 patients was conducted using cetuximab plus irinotecan or cetuximab alone in treatment of EGFR-expressing MCRC [3]. Cetuximab was shown to lengthen the time to disease progression by 4.2 months in the monotherapy arm and 5.7 months in combination arm. In patients with EGFR-positive NSCLC a phase II study by Rosell showed that combination cisplatin/vinorelbine plus cetuximab resulted in an overall response rate of 32%, compared to 20% with cisplatin/vinorelbine alone [5]. The continuing research of cetuximab is helping to determine which populations of patient will benefit most from Anti-EGFR therapy. Currently most evidence points towards the use of cetuximab in combination with other chemotherapeutic regimens as the best option for treatment in EGFR positive tumors.

Epidermal growth factor receptors are ubiquitous, thus potential for exuberant reactions including adverse events is high. Moreover, due to the diverse tissues expressing EGRF, adverse reactions manifest in many ways. Although dermatologic reactions represent the vast majority of adverse events, occurring in between 30-90% of patients depending on the severity and study examined [6, 7], many other side effects occur with cetuximab therapy. Other adverse events increased above control groups included gastrointestinal complaints (19-59%) and headache (19%) [3]. Cextuximab infusion reactions took place in between 15 and 20% of subjects [3].

There have only been rare reports of pulmonary side effects with cetuximab. Interstitial lung disease was reported in 4 of 1,570 (0.25%) patients with advanced colorectal cancer [3]. There have also been reports of interstitial pneumonitis with non-cardiogenic pulmonary edema [8]. The use of cetuximab in combination regimens potentially clouds side effect profiles.

Pulmonary complications in the setting of chemotherapy lead to increased morbidity and severe reactions are associated with mortality. Cetuximab, like many other cancer therapies, has been demonstrated to cause a wide range of respiratory effects from mild dyspnea to a fatality due adverse pulmonary events. The purpose of this investigation is to compile a comprehensive list of pulmonary adverse events in the setting of therapy with cetuximab published in the literature in order to better characterize the true incidence of these reactions. A better understanding of the prevalence may help the clinician respond appropriately to specific symptom changes during the therapeutic window with a hope of improving patient care.

Methods

We performed a MEDLINE™ search of the English language literature using the search terms: "cetuximab" or "Erbitux" with limits to include only human studies to develop a complete index of trials or reports. Inclusion criteria were clinical trials, meta-analyses, or randomized controlled trials that included the search terms and cited adverse events. The reference lists from each of these manuscripts were scanned to isolate articles not obtained in the MEDLINE® search to complete our database. Studies were excluded if they did not list adverse events.

Data extracted from each report included number of patients, controls, type of cancer, coincident chemotherapy administration, and information regarding pulmonary complications. Pulmonary complications included the incidence of symptoms related to the respiratory system including dyspnea, cough, wheezing, pneumonia, hypoxemia, respiratory insufficiency/failure, pulmonary embolus, pleural effusion, and non-specific respiratory disorders. Incidences of these pulmonary complications were obtained from each study's control group if available and compared between the patients that received cetuximab and those who did not. Infusion reactions were treated as a separate complication to cetuximab and were not included in this analysis, although in many individuals, symptoms of shortness of breath and chest tightness may be encompassed by this type of reaction [9].

Data Analysis and Statistics

Data is presented as the number of patients and percentage receiving the study medication as well as means (± SD) where appropriate. Comparisons between groups were made using Chi-Square or students t-test where appropriate, and statistical significance was set as p < 0.05.

Results

Using our search criteria defined above, a total of 245 articles were obtained for review. From this complete group, 192 articles were excluded for not meeting inclusion criteria. Reasons for exclusion were: non-pulmonary focus (dermatologic side effects), duplicate patient populations, case reports not relevant to pulmonary side effects, focus on pharmacokinetics, omission of side effects, or non-cetuximab trials. A total of 53 studies (Table 1) met inclusion and were included in the analysis [5, 8, 1060].

Table 1 Studies included in the analysis including first author, year of publication, type of trial and combined therapy, and pulmonary adverse reactions.

The majority of clinical trials focused on the treatment of colorectal cancers with head/neck, lung, and hepatobiliary or pancreatic making up the next largest groups (Table 1). Similarly, most of the studies examined were completed as Phase I or II trials with the focus on refractory and metastatic disease (Table 2).

Table 2 Number and type of trials broken into groups according to cancer type.

A total of 7,411 patients were included in the 53 studies reviewed including 4,436 (59.8%) patients who received cetuximab either alone or in conjunction with other chemotherapeutic medications or radiation therapy. 2,596 (41.4%) patients were in the control groups from these investigations who received the same chemotherapy or radiation therapy without cetuximab (Table 3).

Table 3 Number of patients included by trial type.

Pulmonary Reactions

A total of 459 patients (10.3%) in the cetuximab group had adverse pulmonary reactions compared to 221 (8.5%) who received standard, non-cetuximab therapy (p < 0.02). Studies focusing on colorectal cancer, lung cancer, and head-neck cancer had sufficient numbers in both the cetuximab and control groups to compare pulmonary complications; however, hepatobiliary, pancreatic, breast, ovarian, and cutaneous cancer studies lacked adequate numbers of control patients to compare these complications.

Colorectal cancer studies demonstrate a low rate of pulmonary complications overall with 3.41% incidence in the cetuximab group versus 2.56% in the control patients (p = NS). The most common side effect was dyspnea in these studies making up more than 90% of the adverse reactions.

Pulmonary adverse events were much more common, as would be expected in NSCLC trials with an incidence of 18.7% in the cetuximab group versus 12.2% in the control arms (p < 0.001). Similarly, dyspnea made up the majority of pulmonary adverse events (13.2% vs 9.2%, p < 0.02) with other significant differences occurring in the incidence of pneumonitis (1.1% versus 0.0%, p < 0.001) being worse in the cetuximab groups.

For head-neck cancer studies, the overall rates of pulmonary complications were similar between the cetuximab and control groups (17.9% versus 20.1%, p = NS), but favored the cetuximab group. Dyspnea was more common in the cetuximab group (8.7%) than the control group (5%, p < 0.02) in Head and Neck Cancer Trials. Conversely, there were fewer patients with increased sputum production (3.0% versus 6.6%, p < 0.01) and cough (4.5% versus 7.8%, p < 0.01) in the control group compared to the cetuximab group. From all studies, the difference in other pulmonary adverse events appears to be similar (Table 4).

Table 4 Combined pulmonary adverse events cited in clinical trials.

Discussion

Overall, cetuximab seems to increase the incidence of adverse pulmonary reactions compared to controls, although the absolute difference between groups is low (<2%). The severity of the pulmonary complications was not well described in most of the included studies, but did not increase mortality rates. To the contrary, if survival benefits were not demonstrated, almost universally, there was an increase in progression free survival or stability of malignancy in these trials. To this point, the difference between statistical significance and clinical significance should also be examined in relation to the pulmonary reactions. For all clinical trials except NSCLC, the differences in pulmonary adverse events between those treated with and without cetuximab are small. Dyspnea and cough, though increased in the cetuximab groups, did not appear to limit the therapeutic course.

The observation of increased pulmonary adverse events in patients with NSCLC when compared to controls was striking. Again, most of the adverse reactions in these patients were dyspnea or respiratory insufficiency, and were not noted to be treatment limiting. Although the mechanism for increased symptoms in patients with NSCLC is not well defined, it is not surprising that those with a site of action in the lung would suffer from exuberant local effects. Pneumonitis was seen in most patients (71%) treated with cetuximab in combination with radiation therapy for NSCLC, although there was no control group in this study for comparison [56]. These patients had advanced disease and were treated with a radiation dose of 64Gy to the lungs, which is well above the threshold for pneumonitis with radiation alone[61] As expected, treatment of head/neck cancers in these trials had high overall rates of pulmonary adverse events, although there were no significant differences between those who received cetuximab and those who did not.

Severe adverse reactions were not common in clinical trials using cetuximab. Interstitial lung disease, cited as a rare complication in the medication's package insert, was not described in the clinical trials included in this review with the exception of a case report of two post-lung transplantation patients treated with cetuximab for cutaneous malignancy. Obviously, there are likely confounding factors which may have predisposed this select population to the development of diffuse alveolar damage. For those described in the cetuximab package insert, interstitial lung disease was present before the institution of cetuximab therapy for malignancy. Arguably, the increase in pulmonary symptoms in these patients may have been more a manifestation of ILD progression than as an effect of the therapeutic. However, the presence of antecedent parenchymal lung disease may abrogate the utility of cetuximab in select patients. Pulmonary embolism, also considered a severe reaction, occurred in small numbers of patients in the groups analyzed herein.

An association between the presence of malignancy in the lung, regardless of primary origin, and pulmonary adverse events could not be determined from this investigation. Of the 43 non-lung cancer studies included in our series only 9 reported the location of metastatic disease. When combined with studies of lung cancer, 17% of this cohort reported direct pulmonary involvement of cancer. In those defining the sites of metastatic foci, the lungs were involved in 46.0 ± 10% of patients. Primary or metastatic involvement of the lung with any cancer could account for patients experiencing pulmonary adverse events when treated with Cetuximab. Unfortunately, a more clear relationship is limited by the presentation of the data in the original studies.

Our investigation suffers from several limitations which should be pointed out. First, it is a compilation of clinical trials, most of which are early phase, with limited numbers including control populations available for comparison of pulmonary adverse events. Most of the studies examined only cited positive adverse events, omitting negative responses to pulmonary symptom changes. This may lead to an over-estimation of the absolute incidence of pulmonary-specific complications. Conversely, transfusion reactions and sepsis which often include symptoms such as dyspnea or respiratory insufficiency were not included in the present analysis due to lack of a clear definition. There were significant differences in the duration of Cetuximab therapy before pulmonary complications were reported in the clinical trials, ranging from 1 week into therapy to more than several months. This also limits the generalizability of the summation data. Finally, although there appears to be an increase in the incidence of pulmonary adverse events with cetuximab therapy, there is no clearly defined causal relationship that can be proven as mechanistic understandings are lacking. Despite these limitations, we believe that this investigation adds to the sparse literature describing the pulmonary adverse events related to cetuximab therapy.

Conclusion

Cetuximab (Erbitux® ImClone, Branchburg, NJ) therapy, in combination or as monotherapy, is efficacious in the treatment of colorectal, head/neck, lung and possibly other cancers. Although there is an overall increase in the incidence of pulmonary adverse events with this treatment, there seems to be sparse evidence suggesting treatment limitations related to these complications. Particular attention should be given to cetuximab recipients with underlying parenchymal lung disease and those with NSCLC, in particular in conjunction with radiation therapy, as these groups may have more severe pulmonary reactions.

Abbreviations

ILD:

Interstitial lung disease

NSCLC:

Non-small cell lung cancer

SCCHN:

Squamous cell cancer/head and neck.

References

  1. 1.

    Walsh G: Biopharmaceutical benchmarks 2006. Nat Biotechnology. 2006, 24: 769-776. 10.1038/nbt0706-769.

    CAS  Article  Google Scholar 

  2. 2.

    Giezen T, Mantel-Teeuwisse A, Straus S, Schellekens H, Leufkens H, Egberts A: Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA. 2008, 300: 1887-1896. 10.1001/jama.300.16.1887.

    CAS  Article  Google Scholar 

  3. 3.

    Inclone Syetems Incorporated NYN, Bristol-Myers Squibb Co PN: Erbitux (Cetuximab) Package Insert. 2008

    Google Scholar 

  4. 4.

    Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, Greene M: ErbB receptors: from oncogenes to targeted cancer therapies. Journal Clinical Investigation. 2007, 117: 2051-2058. 10.1172/JCI32278.

    CAS  Article  Google Scholar 

  5. 5.

    Rosell R, Robinet G, Szczesna A, Ramlau R, Costenla M, Mennecier B, Pfiefer W, O'Bryne K, Welte T, Kolb R, Pirker R, Chemaissani A, Perol M, Ranson M, Ellis P, Pilz K, Reck M: Randomized pahse II study of cetuximab plus cisplatin/vinorelbine compasred with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small cell lung cancer. Ann Oncology. 2008, 19: 362-369. 10.1093/annonc/mdm474.

    CAS  Article  Google Scholar 

  6. 6.

    Monti M, Motta S: Clinical management of cutaneous toxicity of anti-EGFR agents. Int J Biol Markers. 2007, 22: S53-S61.

    CAS  Google Scholar 

  7. 7.

    Saif MW, Kim R: Incidence and management of cutaneous toxicities associated with cetuximab. Expert Opin Drug Saf. 2007, 6: 175-182. 10.1517/14740338.6.2.175.

    CAS  Article  Google Scholar 

  8. 8.

    Leard L, Cho B, Jones K, Hays S, Tope W, Golden J, Hoopes C: Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab. J Heart Lung Transplant. 2007, 26: 1340-1344. 10.1016/j.healun.2007.09.019.

    Article  Google Scholar 

  9. 9.

    Patel D, Goldberg R: Cetuximab-associated infusion reactions: pathology and Management. Oncology. 2006, 20: 1373-1382.

    Google Scholar 

  10. 10.

    Arnold D, Hohler T, Dittrich C, Lordick F, Seufferlein T, Riemann J, Woll E, Herrmann T, Zubel A, Schmoll H: Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. Ann Oncology. 2008, 19: 1442-1449. 10.1093/annonc/mdn150.

    CAS  Article  Google Scholar 

  11. 11.

    Asnacios A, Fartoux L, Romano O, Tesmoingt C, Louafi SS, Mansoubakht T, Artru P, Poynard T, Rosmorduc O, Hebbar M, Taieb J: Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer. 2008, 112: 2733-2739. 10.1002/cncr.23489.

    CAS  Article  Google Scholar 

  12. 12.

    Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortes-Funes H, Hitt R, Gascon P, Amellal N, Harstrick A, Eckardt A: Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2005, 23: 5568-5577. 10.1200/JCO.2005.07.119.

    CAS  Article  Google Scholar 

  13. 13.

    Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006, 354: 567-578. 10.1056/NEJMoa053422.

    CAS  Article  Google Scholar 

  14. 14.

    Bornr M, Koeberle D, Von Moos R, Saletti P, Rauch D, Hess V, Trojan A, Helbling D, Pestalozzi B, Caspar C, Ruhstaller T, Roth A, Kappeler A, Dietrich D, Lanz D, Mingrone W, Swiss Group for Clinical Cancer Research (SAKK) BS: Adding cetuximab to capecitabine plus oxaliplatin (XELOX)in first-line treatment of metastatic colorectal cancer: a rnadomized phase II trial of the Swiss Group for Clinical Research SAKK. Ann Oncology. 2008, 19: 1288-1289. 10.1093/annonc/mdn058.

    Article  Google Scholar 

  15. 15.

    Bourhis J, Rivera F, Mesia R, Awada A, Geoffrois L, Borel C, Humblet Y, Lopez-Pousa A, Hitt R, Vega Villegas ME, Duck L, Rosine D, Amellal N, Schueler A, Harstrick A: Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2006, 24: 2866-2872. 10.1200/JCO.2005.04.3547.

    CAS  Article  Google Scholar 

  16. 16.

    Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA: Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005, 23: 8646-8654. 10.1200/JCO.2005.02.4646.

    Article  Google Scholar 

  17. 17.

    Butts CA, Bodkin D, Middleman EL, Englund CW, Ellison D, Alam Y, Kreisman H, Graze P, Maher J, Ross HJ, Ellis PM, McNulty W, Kaplan E, Pautret V, Weber MR, Shepherd FA: Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol. 2007, 25: 5777-5784. 10.1200/JCO.2007.13.0856.

    CAS  Article  Google Scholar 

  18. 18.

    Cascinu S, Berardi R, Labianca R, Siena S, Falcone A, Aitini E, Barni S, Di CF, Dapretto E, Tonini G, Pierantoni C, Artale S, Rota S, Floriani I, Scartozzi M, Zaniboni A: Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncol. 2008, 9: 39-44. 10.1016/S1470-2045(07)70383-2.

    CAS  Article  Google Scholar 

  19. 19.

    Chan AT, Hsu MM, Goh BC, Hui EP, Liu TW, Millward MJ, Hong RL, Whang-Peng J, Ma BB, To KF, Mueser M, Amellal N, Lin X, Chang AY: Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol. 2005, 23: 3568-3576. 10.1200/JCO.2005.02.147.

    CAS  Article  Google Scholar 

  20. 20.

    Cunningham D, Humblet Y, Siena S, Khayat D, Blieberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E: Cetuximab monotherapy and Cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. New England Journal of Medicine. 2004, 351: 337-345. 10.1056/NEJMoa033025.

    CAS  Article  Google Scholar 

  21. 21.

    Gamucci T, Nelli F, Cianci G, Grassi G, Moscetti L, Sperduti I, Zeuli M, Cortesi E, D'Auria G, Pollera C: A phase II study of cetuximab/irinotecan in patients with heavily pretreated metastatic colorectal cancer: predictive value of early specific toxicities. Clinical Colorectal Cancer. 2008, 7: 273-279. 10.3816/CCC.2008.n.035.

    CAS  Article  Google Scholar 

  22. 22.

    Gebbia V, Del Prete S, Borsellino N, Ferrau F, Tralongo P, Verderame F, Leonardi V, Capasso E, Maiello E, Bordonaro R, Stinco S, Agostara B, Barone C: Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience. Clinical Colorectal Cancer. 2006, 5: 422-428. 10.3816/CCC.2006.n.013.

    Article  Google Scholar 

  23. 23.

    Hanna N, Lilenbaum R, Ansari R, Lynch T, Govindan R, Janne PA, Bonomi P: Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol. 2006, 24: 5253-5258. 10.1200/JCO.2006.08.2263.

    CAS  Article  Google Scholar 

  24. 24.

    Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N, Hong WK, Kies MS: Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol. 2005, 23: 5578-5587. 10.1200/JCO.2005.07.120.

    CAS  Article  Google Scholar 

  25. 25.

    Hofheinz R, Horisberger K, Woernle C, Wenz F, Kraus-Tiefenbacher U, Kahler G, Dinter D, Grobholz R, Heeger S, Post S, Hochhaus A, Willeke F: Phase I trial cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer. Int Journal Radiation Oncology Biol Phys. 2006, 66: 1384-1390. 10.1016/j.ijrobp.2006.07.005.

    CAS  Article  Google Scholar 

  26. 26.

    Ibrahim E, Zeeneldin A, Al-Gahmi A, Sallam Y, Fawzi E, Bahadur Y: Safety and efficacy of cetuximab-chemotherapy combination in Saudi patients with metastatic colorectal cancer. Indian J Cancer. 2007, 44: 56-61. 10.4103/0019-509X.35812.

    Article  Google Scholar 

  27. 27.

    Jonker D, O'Callaghan C, Karapetis C, Zalcberg J, Tu D, Au H, Berry S, Krahn M, Price T, Simes R, Tebbutt N, van Hazel G, Wierzbicki R, Langer C, Moore M: Cetuximab for the treatment of colorectal cancer. New England Journal of Medicine. 2007, 357: 2040-2048. 10.1056/NEJMoa071834.

    CAS  Article  Google Scholar 

  28. 28.

    Konner J, Schilder RJ, DeRosa FA, Gerst SR, Tew WP, Sabbatini PJ, Hensley ML, Spriggs DR, Aghajanian CA: A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. Gynecol Oncol. 2008, 110: 140-145. 10.1016/j.ygyno.2008.04.018.

    CAS  Article  Google Scholar 

  29. 29.

    Koo D, Lee J, Kim T, Chang H, Ryu M, Lee S, Kim M, Sym S, Lee J, Kang Y: A phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer. J Korean Med Sci. 2007, 22: S98-S103. 10.3346/jkms.2007.22.S.S98.

    CAS  Article  Google Scholar 

  30. 30.

    Lenz H, Van Cutsem E, Khambata-Ford S, Mayer R, Gold P, Stella P, Mirtsching B, Cohn A, Pippas A, Azarnia N, Tsuchihashi Z, Mauro D, Rowinsky E: Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clinical Oncology. 2006, 24: 4914-4921. 10.1200/JCO.2006.06.7595.

    CAS  Article  Google Scholar 

  31. 31.

    Machiels JP, Sempoux C, Scalliet P, Coche JC, Humblet Y, Van CE, Kerger J, Canon JL, Peeters M, Aydin S, Laurent S, Kartheuser A, Coster B, Roels S, Daisne JF, Honhon B, Duck L, Kirkove C, Bonny MA, Haustermans K: Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Ann Oncol. 2007, 18: 738-744. 10.1093/annonc/mdl460.

    Article  Google Scholar 

  32. 32.

    Martin-Martorell P, Rosello S, Rodriguez-Braun E, Chirivella I, Bosch A, Cervantes A: Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial. Br J Cancer. 2008, 99: 455-458. 10.1038/sj.bjc.6604530.

    CAS  Article  Google Scholar 

  33. 33.

    Modi S, D'Andrea G, Norton L, Yao TJ, Caravelli J, Rosen PP, Hudis C, Seidman AD: A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer. Clin Breast Cancer. 2006, 7: 270-277. 10.3816/CBC.2006.n.040.

    CAS  Article  Google Scholar 

  34. 34.

    Neyns B, Aerts M, Van NY, Fontaine C, De CL, Schallier D, Vanderauwera J, De MF, Vandenbroucke F, Everaert H, Meert V, De MJ, De RM, Delvaux G, De GJ: Cetuximab with hepatic arterial infusion of chemotherapy for the treatment of colorectal cancer liver metastases. Anticancer Res. 2008, 28: 2459-2467.

    CAS  Google Scholar 

  35. 35.

    Paule B, Herelle MO, Rage E, Ducreux M, Adam R, Guettier C, Bralet MP: Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas. Oncology. 2007, 72: 105-110. 10.1159/000111117.

    CAS  Article  Google Scholar 

  36. 36.

    Pessino A, Artale S, Sciallero S, Guglielmi A, Fornarini G, Andreotti IC, Mammoliti S, Comandini D, Caprioni F, Bennicelli E, Andretta V, Siena S, Sobrero A: First-line single-agent cetuximab in patients with advanced colorectal cancer. Ann Oncol. 2008, 19: 711-716. 10.1093/annonc/mdm516.

    CAS  Article  Google Scholar 

  37. 37.

    Pfister DG, Su YB, Kraus DH, Wolden SL, Lis E, Aliff TB, Zahalsky AJ, Lake S, Needle MN, Shaha AR, Shah JP, Zelefsky MJ: Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol. 2006, 24: 1072-1078. 10.1200/JCO.2004.00.1792.

    CAS  Article  Google Scholar 

  38. 38.

    Pinto C, DI FF, Siena S, Cascinu S, Rojas Llimpe FL, Ceccarelli C, Mutri V, Giannetta L, Giaquinta S, Funaioli C, Berardi R, Longobardi C, Piana E, Martoni AA: Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol. 2007, 18: 510-517. 10.1093/annonc/mdl459.

    CAS  Article  Google Scholar 

  39. 39.

    Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB, Saleh MN, Carey D, LoBuglio AF, Wheeler RH, Cooper MR, Waksal HW: Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol. 2001, 19: 3234-3243.

    CAS  Google Scholar 

  40. 40.

    Robert F, Blumenschein G, Herbst RS, Fossella FV, Tseng J, Saleh MN, Needle M: Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol. 2005, 23: 9089-9096. 10.1200/JCO.2004.00.1438.

    CAS  Article  Google Scholar 

  41. 41.

    Rodel C, Arnold D, Hipp M, Liersch T, Dellas K, Iesalnieks I, Hermann RM, Lordick F, Hinke A, Hohenberger W, Sauer R: Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. Int J Radiat Oncol Biol Phys. 2008, 70: 1081-1086.

    Article  Google Scholar 

  42. 42.

    Safran H, Suntharalingam M, Dipetrillo T, Ng T, Doyle LA, Krasna M, Plette A, Evans D, Wanebo H, Akerman P, Spector J, Kennedy N, Kennedy T: Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys. 2008, 70: 391-395.

    CAS  Article  Google Scholar 

  43. 43.

    Saltz LB, Meropol NJ, Loehrer PJ, Needle MN, Kopit J, Mayer RJ: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004, 22: 1201-1208. 10.1200/JCO.2004.10.182.

    CAS  Article  Google Scholar 

  44. 44.

    Secord AA, Blessing JA, Armstrong DK, Rodgers WH, Miner Z, Barnes MN, Lewandowski G, Mannel RS: Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. Gynecol Oncol. 2008, 108: 493-499. 10.1016/j.ygyno.2007.11.029.

    CAS  Article  Google Scholar 

  45. 45.

    Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J, Lenz HJ, Borg C, Middleton G, Kroning H, Luppi G, Kisker O, Zubel A, Langer C, Kopit J, Burris HA: EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 2008, 26: 2311-2319. 10.1200/JCO.2007.13.1193.

    CAS  Article  Google Scholar 

  46. 46.

    Souglakos J, Kalykaki A, Vamvakas L, Androulakis N, Kalbakis K, Agelaki S, Vardakis N, Tzardi M, Kotsakis AP, Gioulbasanis J, Tsetis D, Sfakiotaki G, Chatzidaki D, Mavroudis D, Georgoulias V: Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy. Ann Oncol. 2007, 18: 305-310. 10.1093/annonc/mdl392.

    CAS  Article  Google Scholar 

  47. 47.

    Tabernero J, Van CE, az-Rubio E, Cervantes A, Humblet Y, Andre T, Van Laethem JL, Soulie P, Casado E, Verslype C, Valera JS, Tortora G, Ciardiello F, Kisker O, de GA: Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2007, 25: 5225-5232. 10.1200/JCO.2007.13.2183.

    CAS  Article  Google Scholar 

  48. 48.

    Thienelt CD, Bunn PA, Hanna N, Rosenberg A, Needle MN, Long ME, Gustafson DL, Kelly K: Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol. 2005, 23: 8786-8793. 10.1200/JCO.2005.03.1997.

    Article  Google Scholar 

  49. 49.

    Tol J, Koopman M, Rodenburg CJ, Cats A, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, Mol L, Antonini NF, Punt CJ: A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol. 2008, 19: 734-738. 10.1093/annonc/mdm607.

    CAS  Article  Google Scholar 

  50. 50.

    Vermorken JB, Trigo J, Hitt R, Koralewski P, az-Rubio E, Rolland F, Knecht R, Amellal N, Schueler A, Baselga J: Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007, 25: 2171-2177. 10.1200/JCO.2006.06.7447.

    CAS  Article  Google Scholar 

  51. 51.

    Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De RD, Bokemeyer C, Schueler A, Amellal N, Hitt R: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008, 359: 1116-1127. 10.1056/NEJMoa0802656.

    CAS  Article  Google Scholar 

  52. 52.

    Vincenzi B, Santini D, Rabitti C, Coppola R, Beomonte ZB, Trodella L, Tonini G: Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. Br J Cancer. 2006, 94: 792-797. 10.1038/sj.bjc.6603018.

    CAS  Article  Google Scholar 

  53. 53.

    Xiong HQ, Rosenberg A, LoBuglio A, Schmidt W, Wolff RA, Deutsch J, Needle M, Abbruzzese JL: Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol. 2004, 22: 2610-2616. 10.1200/JCO.2004.12.040.

    CAS  Article  Google Scholar 

  54. 54.

    Zhu AX, Stuart K, Blaszkowsky LS, Muzikansky A, Reitberg DP, Clark JW, Enzinger PC, Bhargava P, Meyerhardt JA, Horgan K, Fuchs CS, Ryan DP: Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer. 2007, 110: 581-589. 10.1002/cncr.22829.

    CAS  Article  Google Scholar 

  55. 55.

    Gridelli C, Morabito A, Gebbia V, Mencoboni M, Carrozza F, Vigano MG, Verusio C, Bollina R, Mattioli R, Valerio MR, Valmadre G, Maione P, Rossi A, Cascone T, Morgillo F, Di MM, Piccirillo MC, Gallo C, Perrone F, Ciardiello F: Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. Lung Cancer. 2009

    Google Scholar 

  56. 56.

    Hughes S, Liong J, Miah A, Ahmad S, Leslie M, Harper P, Prendiville J, Shamash J, Subramaniam R, Gaya A, Spicer J, Landau D: A brief report on the safety study of induction chemotherapy followed by synchronous radiotherapy and cetuximab in stage III non-small cell lung cancer (NSCLC): SCRATCH study. J Thorac Oncol. 2008, 3: 648-651. 10.1097/JTO.0b013e3181757a60.

    Article  Google Scholar 

  57. 57.

    Belani CP, Schreeder MT, Steis RG, Guidice RA, Marsland TA, Butler EH, Ramalingam SS: Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study. Cancer. 2008, 113: 2512-2517. 10.1002/cncr.23902.

    CAS  Article  Google Scholar 

  58. 58.

    Pirker R, Pereira JR, Szczesna A, von PJ, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, O'Byrne K, de MF, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009, 373: 1525-1531. 10.1016/S0140-6736(09)60569-9.

    CAS  Article  Google Scholar 

  59. 59.

    Shin DM, Donato NJ, Perez-Soler R, Shin HJ, Wu JY, Zhang P, Lawhorn K, Khuri FR, Glisson BS, Myers J, Clayman G, Pfister D, Falcey J, Waksal H, Mendelsohn J, Hong WK: Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res. 2001, 7: 1204-1213.

    CAS  Google Scholar 

  60. 60.

    Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, D'Andrea G, Seidman A, Norton L, Gunnett K, Falcey J, Anderson V, Waksal H, Mendelsohn J: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol. 2000, 18: 904-914.

    CAS  Google Scholar 

  61. 61.

    Park K, Chung F, Chun M, Suh F: Radiation-Induced Ling Disease and the impact of Radiation Methods in Imaging Features. RadioGraphics. 2000, 20: 983-998.

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Jeffrey B Hoag.

Additional information

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

JH conceived and designed the study and participated in writing. AA participated in data gathering, study screening, and study coordination. TD participated in data gathering, study screening, and study coordination. JL participated in statistical analysis of the study and study design. RW participated in study design and data analysis. ML performed oversight of study design, coordination, and writing. All authors read and approved the final manuscript.

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Hoag, J.B., Azizi, A., Doherty, T.J. et al. Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review. J Exp Clin Cancer Res 28, 113 (2009). https://doi.org/10.1186/1756-9966-28-113

Download citation

Keywords

  • Epidermal Growth Factor Receptor
  • Cetuximab
  • Interstitial Lung Disease
  • Pulmonary Complication
  • Vascular Endothelial Growth Factor Production